Roberto Iacovelli: Insights into the use of tumor tissue or ctDNA-based testing at ESMO Asia24
Roberto Iacovelli, Medical Oncologist at Gemelli Polyclinic Foundation IRCCS, shared a post on X:
“Elena Castro gave us valuable insights into the use of tumor tissue or ctDNA-based testing at ESMO Asia24. Regarding genes, BRCA1/2 is the minimum but need to be ready for HRR and PTEN.”
More posts featuring Roberto Iacovelli.
Dr. Roberto Iacovelli, is a medical oncologist at Gemelli Polyclinic Foundation IRCCS in Rome, Italy. With a focus on genitourinary cancers, his research focuses on metastatic renal cell carcinoma, prostate, and bladder cancer, exploring predictive factors and therapy sequencing.
Dr. Iacovelli’s contributions include over 150 publications in peer-reviewed journals and numerous awards for his work, including the ASCO Cancer Foundation Merit Award in 2011.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023